The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Location contact
Darren Mays, MPH, PhD
CONTACT
Darren Mays, MPH, PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07802054
This is an online cross-sectional experimental survey study examining two cancer communication questions: 1) What features of social media messages communicating the breast cancer risks from alcohol consumption will motivate young adult women to drink less? and 2) Do message features differ in their persuasive effects based on young adult women's alcohol consumption behavior?
Trial opening soon.
Get Notified18 year–25 year
Female
Interventional
Not applicable
Columbus, Ohio, 43210, United States
Darren Mays, MPH, PhD
CONTACT
Darren Mays, MPH, PhD
PRINCIPAL_INVESTIGATOR
This is an online cross-sectional experimental study to examine the effects of features of social media messages in young adult women ages 18-25 who drink alcohol based on valid, self-report outcomes. Within the survey, participants will be randomized to view messages in one of nine conditions in a 3x3 factorial design with baseline alcohol consumption as a within-participants factor to test the effects of social media message features (content, persuasive themes) on participant responses. We will also compare the effects of message features for young women who drink within recommended limits (1 drink/day or less on average) and those who exceed recommended drinking limits.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Risk message content
Efficacy Message Content
Messages with information about alcohol industry deception
Message content with information about why young adult women are susceptible to breast cancer risk from alcohol consumption
Message content with information about the mechanism by which alcohol contributes to increased breast cancer risk
Time frame: This assessment is administered immediately after participants view study messages on Day 1
We will assess message perceptions using a valid, reliable measure with six questions about whether participants thought the messages were worth remembering, grabbed their attention, and were informative, powerful, convincing, and meaningful. Responses are on a five-point Likert scale from 1 (Strongly disagree) to 5 (Strongly agree).
For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean. Higher values are considered a better outcome.
Time frame: This assessment is administered immediately after participants view study messages on Day 1
We will capture message effects perceptions using the abbreviated effects perceptions scale. Items include questions about how much the messages made them feel discouraged to drink alcohol, concerned about drinking alcohol, and made them feel that drinking alcohol is unpleasant on a scale from 1 (Strongly disagree) to 5 (Strongly agree). For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean. Higher values are considered a better outcome.
Time frame: This assessment is administered immediately after participants view study messages on Day 1
We will capture emotional responses to the messages using a valid, four item scale. Items are "This message made me angry; irritated; aggravated; and annoyed" with responses on a 5-point Likert scale from 1 (Not likely at all) to 5 (Extremely likely). For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean. Higher values are considered a better outcome.
Time frame: This assessment is administered immediately after participants view study messages on Day 1
We will capture counter-arguing, a measure of whether participants cognitively refute messages, with a valid, three item scale that captures whether participants criticize messages, think of points that go against messages, and are skeptical of the messages. Responses are on a 5-point Likert scale ranging from 1 (Not at all) to 7 (Very much). For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean. Lower values are considered a better outcome.
Time frame: This assessment is administered immediately after participants view study messages on Day 1
Intentions to reduce alcohol consumption in the future will also be assessed with a valid, multi-item scale capturing whether participants will avoid drinking alcohol completely, reduce the number of occasions when they drink alcohol, and reduce the amount of alcohol they consume on drinking occasions with a 1 (Definitely Will Not) to 4 (Definitely Will) response scale. For all message response outcomes, we will sum and average responses to the items to create message-level scores, then compute means across both messages within each condition for a grand mean. Higher values are considered a better outcome.
Contact information is provided by the study sponsor or research team.
Ohio State University Comprehensive Cancer Center
Other
Acronym: MEMO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03134092
Behavior, Chemically-Induced Disorders
Birmingham, Alabama, United States
View Trial DetailsNCT07768462
Behavior, Communication
Palo Alto, California, United States
View Trial DetailsNCT07768488
Behavior, Communication
View Trial DetailsNCT07415057
Behavior, Communication
Oliveira de Azeméis, Portugal
View Trial Details